KRAS and familial pancreatic carcinoma: Clinical mutational profiling of PTOL tumors revealed the same frequency of oncogene (e.g. KRAS) and tumor suppressor gene (e.g. TP53) mutations as the general pancreatic cancer population (Table 1).